Jump to navigation
- Any -
- Any -
Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity
Multi-antigen vaccination for colon cancer treatment and prevention
The ability of NSAIDs to inhibit polyp formation and stimulate Type I immunity is dose dependent
Bexarotene increases tumor CD8+ T cells and improves response to conventional breast chemotherapy in the transgenic mouse mammary tumor model TgMMTV-neu
TLR8 agonist VTX-2337 (motolimod) decreases monocytic myeloid-derived suppressor cells by inducing differentiation to mature antigen-presenting cells
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.
Designing vaccines to prevent breast cancer recurrence or invasive disease
Bexarotene increases tumor CD8+ T cells and improves response to conventional breast chemotherapy in the transgenic mouse mammary tumor model TgMMTV-neu.
HER2 specific adoptive T cells shown to localize and infiltrate all sites of disease using combined SPECT and PET imaging.
Immunologic Monitoring Laboratory (IML)
Adoptive T Cell Therapy
Standard Operating Procedures
FAQ - The Immune System
FAQ - For Trial Participants
In the News
Students and Volunteers
Previous Post-docs and Students